Article Sidebar
Views PDF: 214
TREATMENT OF CHRONIC HEPATITIS B: PRESENT AND FUTURE
Main Article Content
Abstract
Chronic hepatitis B (CHB) can lead to cirrhosis and hepatocellular carcinoma and become a burden on the health sector in many countries. At present, there are still many obstacles to completely eliminating the hepatitis B virus from infected cells. Recently, thanks to the achievements of molecular biology research, the life cycle of HBV and the pathogenesis of CHB have been increasingly understood, which helps to develop potential antiviral therapies targeting different stages in the life cycle of the vi rút.
Article Details
Keywords
Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Covalently closed circular DNA (cccDNA), Nucleoside or nucleotide analogs (NAs), Relaxed-circular partially double-stranded DNA (rcDNA)
References
2. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2018; 15;3(1): 8-19. DOI: 10.1002/hep4.1281. PMID: 30619990; PMCID: PMC6312657.
3. Yapali S, Talaat N, Lok AS. Management of hepatitis B: Our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014; 12:16-26.
4. Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, Voronkova N, Schöneweis K, Pathil A, Burhenne J, Haag M, Schwab M, Haefeli WE, Wiesch JSZ, Alexandrov A, Urban S. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018; 68:S3.
5. Maria G, Emmanuel C, Aurore I, Philippe E, Elodie D, Fleur C, Gregory N, Antoine A, Kara C, Barbara T, Fabien Z. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio. 2022; 13(2): e0288821. PMCID: PMC9040760. PMID: 35389262. DOI: 10.1128/mbio. 02888-21.
6. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP(). Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther. 2010; 18:947-954.
7. Kristie B, Abdullah E, Claudio M, Toni C, Patrick A. Inactivation of Hepatitis B Virus Replication in cultured cells and In Vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013; 21(10):1889-1897. DOI: 10.1038/mt.2013.170.
8. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM. Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. Antimicrob. Agents Chemother. 2012; 56:4277-4288. DOI: 10.1128/AAC.00473-12.
9. Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV Curative Therapies. Liver Int. 2018; 38:102-114. DOI: 10.1111/liv.13656.
10. Yuen MF, Heo J, Jang JW, Yoon J-H, Kweon YO, Park SJ. Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: Phase 2a, randomized, double-blind, placebo-controlled study. J Hepatol. 2020; 73:S49-S50. DOI:10.1016/s0168-8278 (20)30646-2.
11. Tavis JE, Zoidis G, Meyers MJ, Murelli RP. Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. ACS Infect Dis. 2018; 10; 5(5): 655-658. DOI: 10.1021/acsinfecdis.8b00045. PMID: 29565562; PMCID: PMC7202671.
12. Janssen HLA, Hou J, Asselah T, Henry L, Fabien Z, Yasuhito T, Ewa J, Ronald G, Stefan N Shukla U. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 2023; DOI: 10.1136/gutjnl-2022-328041.
13. Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother. 2017; 61:e00560-17. [PMC free article] [PubMed] [Google Scholar]
14. Tang Y, Liang H, Zeng G, Shen S, Sun J. Advances in new antivirals for chronic hepatitis B. Chin Med J (Engl). 2022; 135(5):571-583. DOI: 10.1097/CM9.0000000000001994. PMID: 35120358; PMCID: PMC8920451.